PNPLA2 Recombinant Monoclonal Antibody

Code CSB-RA111385A0HU
Size US$210
Order now
Image
  • Overlay Peak curve showing HepG2 cells stained with CSB-RA111385A0HU (red line) at 1:50. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1µg/1*106cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated Goat Anti-rabbit IgG(H+L) at 1:200 dilution for 35min at 4℃.Control antibody (green line) was rabbit IgG (1µg/1*106cells) used under the same conditions. Acquisition of >10,000 events was performed.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
PNPLA2
Alternative Names
Patatin-like phospholipase domain-containing protein 2 (EC 3.1.1.3) (Adipose triglyceride lipase) (Calcium-independent phospholipase A2) (Desnutrin) (IPLA2-zeta) (Pigment epithelium-derived factor) (TTS2.2) (Transport-secretion protein 2) (TTS2), PNPLA2, ATGL
Species Reactivity
Human
Immunogen
A synthesized peptide derived from Human PNPLA2
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
Rabbit IgG
Clone No.
1H6
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Form
Liquid
Tested Applications
ELISA, FC
Recommended Dilution
Application Recommended Dilution
FC 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Description

A recombinant monoclonal antibody against PNPLA2 was generated through a series of steps, beginning with the immunization of a rabbit using a synthesized peptide derived from human PNPLA2 protein. Subsequently, B cells were isolated from the immunized rabbit, and RNA was extracted from these cells. The extracted RNA was reverse-transcribed into cDNA, which served as a template for extending PNPLA21 antibody genes using degenerate primers. These engineered PNPLA2 antibody genes were incorporated into a plasmid vector and introduced into host cells for expression. The PNPLA2 recombinant monoclonal antibody was then isolated from the cell culture supernatant via affinity chromatography and assessed for its suitability in ELISA and FC applications. It only recognizes human PNPLA2 protein.

PNPLA2/ATGL is a key enzyme involved in the hydrolysis of stored triglycerides, contributing to energy homeostasis, lipid metabolism, and the regulation of adipose tissue function. Its activity is tightly regulated and plays a crucial role in maintaining metabolic health.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Catalyzes the initial step in triglyceride hydrolysis in adipocyte and non-adipocyte lipid droplets. Exhibits a strong preference for the hydrolysis of long-chain fatty acid esters at the sn-2 position of the glycerol backbone. Also has acylglycerol transacylase activity. Acts coordinately with LIPE/HLS and DGAT2 within the lipolytic cascade. Transfers fatty acid from triglyceride to retinol, hydrolyzes retinylesters, and generates 1,3-diacylglycerol from triglycerides. Regulates adiposome size and may be involved in the degradation of adiposomes. May play an important role in energy homeostasis. May play a role in the response of the organism to starvation, enhancing hydrolysis of triglycerides and providing free fatty acids to other tissues to be oxidized in situations of energy depletion.
Gene References into Functions
  1. No difference in the genotype frequency of rs7925131 or rs7942159 in PNPLA2 between the normal free fatty acids (FFA) group and the high FFA group in a Chinese Han population. PMID: 29072982
  2. Non-cardiac ATGL-mediated modulation of the cardiac lipidome may play an important role in the pathogenesis of chronic heart failure. PMID: 29320510
  3. Although we found evidence for moderate association between PNPLA2 tagSNPs and anthropometric and metabolic parameters in our cohort, no evidence for association between polymorphisms in the PNPLA2 gene and the presence and severity of non-alcoholic fatty liver disease was identified. PMID: 26500201
  4. Study reports the derivation of iPSCs from fibroblasts of two Neutral Lipid Storage Disease with Myopathy (NLSDM)patients carrying different ATGL mutations. These iPSCs exhibited defects in neutral lipid metabolism similar to those of NLSDM fibroblasts. NLSDM-iPSCs were able to undergo directed differentiation into cardiomyocytes. PMID: 28391974
  5. Thus, ATGL in leucocytes may be an important biomarker for the diagnosis of TGCV and our assay may provide insights into pathophysiology and elucidate the underlying mechanism of TGCV and related disorders. PMID: 29146190
  6. The ATGL gene was frequently deleted in various forms of human cancers and was associated with poor prognosis. PMID: 27213586
  7. a Snail1-ATGL axis that regulates adipose lipolysis and fatty acid release, is reported. PMID: 27851965
  8. ABHD5 possesses a PNPLA2-independent function in regulating autophagy and tumorigenesis. PMID: 27559856
  9. Oxidative stress decreased the levels of PNPLA2 transcripts with no effect on ALOX5 expression. Exogenous additions of P1 peptide or overexpression of the PNPLA2 gene decreased both LTB4 levels and death of RPE cells undergoing oxidative stress. PMID: 27635633
  10. Results suggest that increased adipose triglyceride lipase (ATGL) expression is associated with increased adiposity and stromal proliferation in patients with pancreatic ductal adenocarcinoma (PDAC). PMID: 28179319
  11. A missense mutation in PNPLA2 is the rare cause of severe dilated cardiomyopathy secondary to neutral lipid storage disease. PMID: 26922712
  12. A novel deletion was identified in PNPLA2 protein from a patient with complete deficiency of adipose triglyceride lipase. PMID: 26803235
  13. Rab32 controls intracellular lipid accumulation through inducing lipolysis via enhancing ATGL expression indirectly. PMID: 26882978
  14. Data indicate that a tumor suppressor mechanism by which G0/G1 switch gene 2 product (G0S2) directly inhibits activity of a key intracellular adipose triglyceride lipase (ATGL). PMID: 26318046
  15. Authors show that rat ATGL, coactivated by rat CGI-58, efficiently hydrolyzes triglycerides and retinyl ester. PMID: 26330055
  16. PNPLA2 mutations were associated with an extended phenotype, including brain involvement in cases of neutral lipid-storage disease with myopathy. PMID: 26600210
  17. Distinct cardiac phenotype between two homozygotes born in a village with accumulation of a genetic deficiency of adipose triglyceride lipase. PMID: 25985012
  18. Study reports the clinical and genetic findings of a neutral lipid storage disease with myopathy family of Italian origin with 3 affected siblings. to highlight the effect that different gene mutations may have on ATGL lipase activity, authors performed a functional characterization of the novel PNPLA2 missense mutations identified in their patients PMID: 25956450
  19. PLIN5 was significantly colocated with ATGL, mitochondria and CGI-58, indicating a close association between the key lipolytic effectors in resting skeletal muscle. PMID: 25054327
  20. PEDF receptor is a transmembrane phospholipase that is required for the survival and antiapoptotic effects of PEDF on retina cells. It has determinants for PEDF binding within its L4 ectodomain that are critical for enzymatic stimulation. PMID: 23818523
  21. Data suggest that PNPLA2 hydrolyzes arachidonic acid from triglycerides in mast cell (MC) lipid droplets; PNPLA2 appears to regulate substrate availability of AA for eicosanoid (PGD2/LTC4) generation/secretion upon MC activation with IgE. PMID: 25114172
  22. Data suggest that pigment epithelium-derived factor (PEDF) and adipose triglyceride lipase (ATGL) may serve as therapeutic targets for managing vascular hyperpermeability in sepsis. PMID: 25700221
  23. Results indicate that the serum adipose triglyceride lipase (ATGL) level may be closely related to obesity. PMID: 25177954
  24. Data indicate that the peptide corresponding to residues Lys-20 to Ala-52 from G0S2 Inhibits ATGL in the nanomolar range. PMID: 25258314
  25. Data indicate that fat-specific protein 27 (FSP27) increases the inhibitory effect of transcription factor Egr1 on the adipose triglyceride lipase (ATGL) promoter. PMID: 24742676
  26. The pathophysiological impact due to defective lipolysis by ATGL deficiency on mitochondrial dysfunction. [Review] PMID: 23827855
  27. our results suggest that inhibition of the major lipolytic enzymes ATGL and HSL by long-chain acyl-CoAs could represent an effective feedback mechanism controlling lipolysis PMID: 24440819
  28. In patients with TGCV, even when hydrolysis of intracellular TG is defective, the marked up-regulation of PPARgamma and related genes may lead to increased uptake of LCFAs, the substrates for TG synthesis. PMID: 24332944
  29. In humans, ATGL has a remarkable effect on cellular lipid droplet handling, and its lack causes both perivisceral, skeletal muscle, and pancreas fat accumulation; in contrast, the impact on whole-body insulin sensitivity and fatty acid metabolism is minor PMID: 23824421
  30. Data indicate that PNPLA2 mutations in neutral lipid storage sisease with myopathy (NLSD with myopathy). PMID: 23232698
  31. Contribution of novel ATGL missense mutations to the clinical phenotype of NLSD-M: a strikingly low amount of lipase activity may preserve cardiac function. PMID: 22990388
  32. PNPLA2 gene mutations are responsible for neutral lipid storage disease with myopathy in Chinese Han patients. PMID: 22832386
  33. UBXD8-mediated recruitment of p97/VCP to LDs increases lipid droplet (LD) size by inhibiting the activity of adipose triglyceride lipase (ATGL), the rate-limiting enzyme in triacylglycerol hydrolysis. PMID: 23297223
  34. These data suggest that elevated levels of ATGL are involved in the exercise-induced enhancement of lipolysis in primary adipocytes. PMID: 22815850
  35. The results demonstrated that adipose triglyceride lipase Ser(404) phosphorylation is not increased in mixed skeletal muscle during moderate-intensity exercise and that AMPK does not appear to be an activating kinase for ATGL Ser(404) in skeletal muscle. PMID: 22713505
  36. Reduced mRNA and protein content of Plin and G0S2 and borderline increased ATGL protein in sc adipose tissue from poorly controlled type 2 diabetic subjects. PMID: 22535977
  37. Resveratrol increased adipose triglyceride lipase gene and protein expressions, an effect that was not observed for hormone-sensitive lipase in human SGBS adipocytes. PMID: 21543206
  38. We have mapped the epitope of the antibody that detects PEDF-R to the coding region of exon 4. PMID: 22183409
  39. Four novel and two previously reported mutations were detected, affecting different parts of the PNPLA2 gene in 6 patients with neutral lipid storage disease PMID: 21544567
  40. the C terminus sequesters ABHD5 and thus inhibits basal ATGL activity PMID: 21757733
  41. GBF1 and ATGL interact directly and in cells, through multiple contact sites on each protein. PMID: 21789191
  42. ATGL knockdown increased monocyte adhesion to the endothelium through enhanced TNFalpha-induced ICAM-1 expression via activation of NFkappaB and PKC. PMID: 21828047
  43. findings are compatible with the notion that the ATGL-G0S2 complex is an important long-term regulator of lipolysis under physiological conditions such as fasting in humans PMID: 21613358
  44. The results suggest a molecular pathway by which PEDF ligand/receptor interactions on the cell surface could generate a cellular signal. PMID: 20237999
  45. Adipose triglyceride lipase (ATGL) levels were inversely correlated with body mass index and positively correlated with insulin sensitivity index. In muscle, ATGL mRNA had a strong positive relationship with carnitine palmitoyltransferase I mRNA. PMID: 21129760
  46. total lipase, ATGL and HSL activities were higher in visceral white adipose tissue of cancer patients compared with individuals without cancer and higher in cancer patients with cachexia compared with cancer patients without cachexia PMID: 21680814
  47. Data indicate that altered ATGL and HSL expression in skeletal muscle could promote DAG accumulation and disrupt insulin signaling and action. PMID: 21498783
  48. interaction of ATGL with CGI-58 increased lipolysis, whereas interaction of ATGL with perilipin 5 decreased lipolysis. PMID: 21393244
  49. 1 out of 13 healthy individuals carried at least one rare mutation of PNPLA2. PMID: 21170305
  50. variants within PNPLA2 may modulate the TG component of the familial combined hyperlipidemia trait, thus implicating PNPLA2 as modifier gene in this lipid disorder PMID: 20832801

Show More

Hide All

Involvement in disease
Neutral lipid storage disease with myopathy (NLSDM)
Subcellular Location
Lipid droplet. Cell membrane; Single-pass type II membrane protein.
Tissue Specificity
Highest expression in adipose tissue. Also detected in heart, skeletal muscle, and portions of the gastrointestinal tract. Detected in normal retina and retinoblastoma cells. Detected in retinal pigment epithelium and, at lower intensity, in the inner seg
Database Links

HGNC: 30802

OMIM: 609059

KEGG: hsa:57104

STRING: 9606.ENSP00000337701

UniGene: Hs.654697

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*